reading retatrutide threads from 2024 and half of it aged badly
reading retatrutide threads from 2024 and half of it aged badly. Not a hot take, just something I have not seen said plainly here.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
I will update this if the picture changes rather than quietly leaving it up.
best — the order this archive was captured in
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
phase 2 data only, and people quote it like it is a label
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
the TRIUMPH programme is still running, so anything definitive is premature
Has anyone posted an independent test on this compound recently?
the energy-expenditure story is mechanistically interesting and clinically unproven
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
not approved anywhere, which is the single most important fact in this board
the phase 2 numbers were striking and they were also 48 weeks in a small population
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
- 1Yes — the comparison threads are apples to oranges and they generate more…9 comments in this branch · started by u/cold_chromatogram_only